Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Japan Govt to Start Omicron Vaccine Distribution from Week of Sept. 19
September 6, 2022
- Tatsumi Kagaku Faces Biz Improvement Order over Discrepant Manufacturing Method, Falsified Records
September 5, 2022
- METI Seeks 7 Billion Yen to Develop Next-Gen Drug Discovery Tech Platform: FY2023 Budget Request
September 5, 2022
- No Major Safety Concerns for COVID-19 Vaccines in Japan: MHLW Panels
September 5, 2022
- Japan to Supply AstraZeneca’s Evusheld Only for COVID-19 Prevention
September 2, 2022
- MHLW Council OKs Public Knowledge-Based Applications for FOLFOX Therapy for Stomach Cancer
September 2, 2022
- Experts Raise Alarm on Declining Attractiveness of Japan Market: New Panel
September 1, 2022
- New Expert Panel on Drug Distribution and Pricing Boots Up; 2-Step Proposals Eyed for Off-Year Revision, 2024 Reform
September 1, 2022
- PM Kishida Vows Earlier Rollout of Omicron Boosters
September 1, 2022
- MHLW Orders Label Revisions for Cyramza, Plaquenil
September 1, 2022
- University of Tokyo Selected as Flagship R&D Site to Orchestrate Japan’s Vaccine Efforts: SCARDA Project
August 31, 2022
- Japan Approves AstraZeneca’s COVID-19 Cocktail Therapy Evusheld
August 30, 2022
- Pfizer’s COVID Booster Approved for Children Aged 5-11 in Japan
August 30, 2022
- LDP Group Eyes Proposal on Generic Distribution, Pricing; Expert Wants Penalty on Healthcare Providers Getting Undue Discounts
August 30, 2022
- AZ’s Asthma Drug Tezepelumab Clears MHLW Panel Review; BMS’ Psoriasis Med, MSD/Sanofi Jabs Too
August 30, 2022
- AstraZeneca’s COVID Cocktail in Line for Approval, Comirnaty Booster for Ages 5-11
August 30, 2022
- Japan Eyes FY2023 Launch of Pandemic Response Agency
August 29, 2022
- MHLW’s Health Service Bureau to Seek Funding for “Income Security System” for Antimicrobials for FY2023
August 29, 2022
- MHLW’s Health Policy Bureau to Seek Budget for Research into Integrating Drug Supply Info, Clarification of Generic Ratio
August 29, 2022
- MHLW Begins Discussions on Potential Use of Non-Doctor/Nurse Healthcare Professionals as Vaccinators
August 29, 2022
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…